CGRP antagonists: unravelling the role of CGRP in migraine

被引：102

作者：

Doods, Henri ^{[1
]}

Arndt, Kirsten ^{[1
]}

Rudolf, Klaus ^{[1
]}

Just, Stefan ^{[1
]}

机构：

[1] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach, Germany

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2007年 / 28卷 / 11期

关键词：

D O I：

10.1016/j.tips.2007.10.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main molecular players is still incomplete, recent preclinical and clinical findings indicate that there is a clear correlation between migraine-associated headache and the release of the neuropeptide calcitonin gene-related peptide (CGRP). BIBN4096 was the first CGRP antagonist to be tested in clinical trials for the treatment of migraine. The proven efficacy of this agent, and also the CGRP antagonist MK0974, to alleviate acute migraine headache provided significant support for the hypothesis that CGRP has an important role in migraine pathophysiology. Moreover, the recently published results from Phase II trials are encouraging and suggest that this new type of drug might offer advantages over existing therapies for patients suffering from migraine and related headaches.

引用

页码：580 / 587

页数：8

共 88 条

[1] A positron emission tomographic study in spontaneous migraine [J].

Afridi, SK ;

Giffin, NJ ;

Kaube, H ;

Friston, KJ ;

Ward, NS ;

Frackowiak, RSJ ;

Goadsby, PJ .

ARCHIVES OF NEUROLOGY, 2005, 62 (08) :1270-1275

[2] A cDNA encoding the calcitonin gene-related peptide type 1 receptor [J].

Aiyar, N ;

Rand, K ;

Elshourbagy, NA ;

Zeng, ZZ ;

Adamou, JE ;

Bergsma, DJ ;

Li, Y .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (19) :11325-11329

[3] Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels [J].

Akerman, S ;

Williamson, DJ ;

Kaube, H ;

Goadsby, PJ .

BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (01) :62-68

[4] Experimental migraine models and their relevance in migraine therapy [J].

Arulmani, U ;

Gupta, S ;

MaassenVanDenBrink, A ;

Centurión, D ;

Villalón, CM ;

Saxena, PR .

CEPHALALGIA, 2006, 26 (06) :642-659

[5] Calcitonin gene-related peptide and its role in migraine pathophysiology [J].

Arulmani, U ;

MaassenVanDenBrink, A ;

Villalón, CM ;

Saxena, PR .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 500 (1-3) :315-330

[6] Migraine: Current concepts and emerging therapies [J].

Arulmozhi, DK ;

Veeranjaneyulu, A ;

Bodhankar, SL .

VASCULAR PHARMACOLOGY, 2005, 43 (03) :176-187

[7]

Bell D, 1996, PHARMACOL REV, V48, P253

[8] Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists [J].

Bell, Ian M. ;

Bednar, Rodney A. ;

Fay, John F. ;

Gallicchio, Steven N. ;

Hochman, Jerome H. ;

McMasters, Daniel R. ;

Miller-Stein, Cynthia ;

Moore, Eric L. ;

Mosser, Scott D. ;

Pudvah, Nicole T. ;

Quigley, Amy G. ;

Salvatore, Christopher A. ;

Stump, Craig A. ;

Theberge, Cory R. ;

Wong, Bradley K. ;

Zartman, C. Blair ;

Zhang, Xu-Fang ;

Kane, Stefanie A. ;

Graham, Samuel L. ;

Vacca, Joseph P. ;

Williams, Theresa M. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) :6165-6169

[9] Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons [J].

Bellamy, J ;

Bowen, EJ ;

Russo, AF ;

Durham, PL .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (08) :2057-2066

[10] Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model [J].

Bolay, H ;

Reuter, U ;

Dunn, AK ;

Huang, ZH ;

Boas, DA ;

Moskowitz, MA .

NATURE MEDICINE, 2002, 8 (02) :136-142

← 1 2 3 4 5 6 7 8 9 →